Brief: Gritstone Bio Announces Interim Phase 2 Data For Individualized Neoantigen Targeting Immunotherapy In Colorectal Cancer
30/09/2024 21:42
Sept 30 (Reuters) - Gritstone bio Inc GRTS.O :
* GRITSTONE BIO ANNOUNCES INTERIM PHASE 2 DATA FOR GRANITE
INDIVIDUALIZED NEOANTIGEN TARGETING IMMUNOTHERAPY IN FRONTLINE
METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
* GRITSTONE BIO INC - GRANITE WELL-TOLERATED WITH NO
TREATMENT
DISCONTINUATIONS DUE TO ADVERSE EVENTS
* GRITSTONE BIO INC - OVERALL SURVIVAL DATA EXPECTED IN 2H
2025
Source text for Eikon: ID:nGNXbvMTJ9
Further company coverage: GRTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gritstone bio
See all newsBrief: Gritstone Bio Inc On Dec 31 2024, Vassiliki “Celia” Economides Became Interim CEO As Well As CFO Of Co
Brief: Gritstone Bio Announces Strengthening Of Maturing Phase 2 PFS Data for GRANITE Study And Provides Business Update
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-PPG Industries, Travelers, ShiftPixy